Review




Structured Review

Karius Inc mcfdna seq
Mcfdna Seq, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/mcfdna+seq/pm41780551-70-29-42
Average 86 stars, based on 1 article reviews
mcfdna seq - by Bioz Stars, 2026-10
86/100 stars

Images

Related Articles

Infection:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

Control:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

Concentration Assay:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

Clinical Proteomics:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

other:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: This study was additionally supported by the National Cancer Institute (R25CA23944; AB), by a St Jude Children’s Research Hospital Comprehensive Cancer Center Developmental Funds Award (JW, CG, and PT), and by non-financial support from Karius, which provided mcfDNA-Seq testing.



Similar Products

99
Plasmidsaurus bulk rna sequencing
Bulk Rna Sequencing, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/RNA-Seq/10__1158_slash_0008___5472__can___26___0823-148-0-5
Average 99 stars, based on 1 article reviews
bulk rna sequencing - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

92
Integrated DNA Technologies xgen methyl-seq lib prep
Xgen Methyl Seq Lib Prep, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/xGen+Methyl-Seq+Lib+Prep/custom%4010009860%4042753031
Average 92 stars, based on 1 article reviews
xgen methyl-seq lib prep - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

86
Thermo Fisher ion total rna seq kit v2
Ion Total Rna Seq Kit V2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/nct04488614-6-19-24
Average 86 stars, based on 1 article reviews
ion total rna seq kit v2 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Karius Inc mcfdna seq
Mcfdna Seq, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/mcfdna+seq/pm41780551-70-29-42
Average 86 stars, based on 1 article reviews
mcfdna seq - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

99
Plasmidsaurus bulk rna seq
( A ) <t>Bulk</t> <t>RNA-seq</t> data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.
Bulk Rna Seq, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/RNA-Seq/pmc13588199-355-7-5
Average 99 stars, based on 1 article reviews
bulk rna seq - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

99
Plasmidsaurus rna sequencing
( A ) <t>Bulk</t> <t>RNA-seq</t> data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.
Rna Sequencing, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/RNA-Seq/pm42748925-806-11-9
Average 99 stars, based on 1 article reviews
rna sequencing - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

99
Complete Genomics Inc stereo-cite proteo-transcriptomics set
( A ) <t>Bulk</t> <t>RNA-seq</t> data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.
Stereo Cite Proteo Transcriptomics Set, supplied by Complete Genomics Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/Stereo-CITE+Proteo-Transcriptomics+Set/custom%40211pt11114%4010%2E1096%2Ffj%2E202502942rrr
Average 99 stars, based on 1 article reviews
stereo-cite proteo-transcriptomics set - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


( A ) Bulk RNA-seq data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.

Journal: Science Advances

Article Title: Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models

doi: 10.1126/sciadv.aef7756

Figure Lengend Snippet: ( A ) Bulk RNA-seq data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.

Article Snippet: Purified RNA was sent to Plasmidsaurus for bulk RNA-seq using the Illumina sequencing technology.

Techniques: RNA Sequencing, In Vivo, In Vitro, Transcriptomics, Biomarker Discovery

( A ) Schematic of validation liver triculture spheroid experiments. Hepatocytes, Kupffer cells, and hepatic stellate cells were seeded in a 10:1:1 ratio in alginate wells and cultured for 11 days. Treatments were initiated on day 3 (D3) and replenished with each medium change. ( B and C ) Quantification of spheroid phenotypes shows that TGFβ1 (10 ng/ml) decreased steatosis, as measured by normalized BODIPY signal (B), while increasing fibrosis, measured by α-SMA in vimentin-positive areas (C). Cotreatment with IFN-α (1000 U/ml) reduced lipid content further and restored α-SMA to baseline expression. a.u., arbitrary units. ( D ) Bulk RNA-seq performed on parallel spheroid cultures reveals strong transcriptional differences associated with the experimental treatments, as evidenced by PCA. ( E ) Pathway activity inference confirms a TGFβ signature associated with PC1 and a JAK-STAT signature associated with PC2. ( F ) Projection of the gene expression data onto TC1 and extra LV 1 preserves clustering by experimental condition. Imaging data are presented as a ratio normalized to the median of the control group. Each point represents an individual spheroid. In all panels, asterisks indicate statistical significance level defined as follows: **** P ≤ 10 –4 , *** P ≤ 10 –3 , and ns for P > 0.05.

Journal: Science Advances

Article Title: Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models

doi: 10.1126/sciadv.aef7756

Figure Lengend Snippet: ( A ) Schematic of validation liver triculture spheroid experiments. Hepatocytes, Kupffer cells, and hepatic stellate cells were seeded in a 10:1:1 ratio in alginate wells and cultured for 11 days. Treatments were initiated on day 3 (D3) and replenished with each medium change. ( B and C ) Quantification of spheroid phenotypes shows that TGFβ1 (10 ng/ml) decreased steatosis, as measured by normalized BODIPY signal (B), while increasing fibrosis, measured by α-SMA in vimentin-positive areas (C). Cotreatment with IFN-α (1000 U/ml) reduced lipid content further and restored α-SMA to baseline expression. a.u., arbitrary units. ( D ) Bulk RNA-seq performed on parallel spheroid cultures reveals strong transcriptional differences associated with the experimental treatments, as evidenced by PCA. ( E ) Pathway activity inference confirms a TGFβ signature associated with PC1 and a JAK-STAT signature associated with PC2. ( F ) Projection of the gene expression data onto TC1 and extra LV 1 preserves clustering by experimental condition. Imaging data are presented as a ratio normalized to the median of the control group. Each point represents an individual spheroid. In all panels, asterisks indicate statistical significance level defined as follows: **** P ≤ 10 –4 , *** P ≤ 10 –3 , and ns for P > 0.05.

Article Snippet: Purified RNA was sent to Plasmidsaurus for bulk RNA-seq using the Illumina sequencing technology.

Techniques: Biomarker Discovery, Cell Culture, Expressing, RNA Sequencing, Activity Assay, Gene Expression, Imaging, Control